This story is from April 06, 2021
Tiger Global eyes PharmEasy stake amid e-pharmacy consolidation
BENGALURU:
Sources aware of the talks said the investment size is yet to be finalised but it would be a mix of primary and secondary capital infusion where some of the early investors may sell parts of their stake in PharmEasy's parent firm API Holdings. “Tiger has been in talks with PharmEasy for several weeks now and it’s progressing steadily.
PharmEasy has got the final approval from antitrust regulator Competition Commission of India (CCI) on the investment from Prosus Ventures (previously Naspers) and now talks with Tiger will move ahead,” one of the people mentioned above said.
As reported by TOI in February, PharmEasy's parent is in the final stages of closing an investment of around $300-$350 million from Prosus Ventures and private equity major
Tiger Global has already invested around $150 million in Indian startups this year, based on investments that have been made public, according to data from Venture Intelligence. Tiger is reportedly in the middle of backing multiple other startups which will take the total size of its investments in India in 2021 to a much bigger figure. Some of Tiger’s current prominent Indian bets include Zomato, Byju’s and Razorpay.
E-pharmacy has been seeing a lot of action. The Tata Group is in the final stages of taking a majority stake in e-pharmacy 1MG. Reliance Industries has entered the space through Netmeds. Amazon is scaling up medicine delivery operations, starting from Bengaluru.
When contacted, PharmEasy co-founder Dhaval Shah and a spokesperson of Tiger Global declined to comment on the matter. Industry reports say about 6 million new households have tried e-pharmacy post the virus outbreak last year, taking the total to 9 million. With a strong second wave of Covid-19 cases in India, online ordering of medicines and lab tests are expected to grow further. Large strategic players are focusing on a higher order frequency, higher average ticket size of purchases, and a bigger healthcare play.
Ready to Master Stock Valuation? ET’s Workshop is just around the corner!
Tiger Global
Management, one of the most fervent backers of Indian startups, is in early-stage talks for an investment in online pharmacy platformPharmEasy
, twopeople aware
of the discussions said. Tiger Global, which recently closed its thirteenth global fund of $6.7 billion, its biggest till date, has been aggressively investing in local startups this year.PharmEasy has got the final approval from antitrust regulator Competition Commission of India (CCI) on the investment from Prosus Ventures (previously Naspers) and now talks with Tiger will move ahead,” one of the people mentioned above said.
As reported by TOI in February, PharmEasy's parent is in the final stages of closing an investment of around $300-$350 million from Prosus Ventures and private equity major
TPG Capital
. This too is a mix of primary and secondary share sale. In a secondary transaction, existing investors sell their stake (partial or full) to new investors and the money does not go to the company coffers.Tiger Global has already invested around $150 million in Indian startups this year, based on investments that have been made public, according to data from Venture Intelligence. Tiger is reportedly in the middle of backing multiple other startups which will take the total size of its investments in India in 2021 to a much bigger figure. Some of Tiger’s current prominent Indian bets include Zomato, Byju’s and Razorpay.
E-pharmacy has been seeing a lot of action. The Tata Group is in the final stages of taking a majority stake in e-pharmacy 1MG. Reliance Industries has entered the space through Netmeds. Amazon is scaling up medicine delivery operations, starting from Bengaluru.
When contacted, PharmEasy co-founder Dhaval Shah and a spokesperson of Tiger Global declined to comment on the matter. Industry reports say about 6 million new households have tried e-pharmacy post the virus outbreak last year, taking the total to 9 million. With a strong second wave of Covid-19 cases in India, online ordering of medicines and lab tests are expected to grow further. Large strategic players are focusing on a higher order frequency, higher average ticket size of purchases, and a bigger healthcare play.
Ready to Master Stock Valuation? ET’s Workshop is just around the corner!
Popular from Business
- Switzerland suspends most favoured nation status to India, cites Nestle verdict
- Switzerland revokes MFN status to India over SC Nestle order
- India shouldn't build another LLM: Nandan Nilekani
- Aadhaar Card update for free: Deadline for free update ends on December 14, 2024 - how to update Aadhaar online
- Gold rally may slow down in 2025: WGC
end of article
Trending Stories
- H-1B visas: Approvals for Indian IT firms half since 2015! Elon Musk’s Tesla shows significant increase
- India to be global submarine building hub? Germany’s Thyssenkrupp eyes P75I contract, offers to make submarines here
- Aadhaar Card update for free: Deadline for free update ends on December 14, 2024 - how to update Aadhaar online
- Akasa Air gets funding boost! Azim Premji-Ranjan Pai family offices to buy significant minority stake
- Stock market today: BSE Sensex opens over 200 points down; Nifty50 below 24,500
- New bank account, locker rules soon? Banking Amendment Bill allows up to 4 nominees - check what’s about to change
- Elon Musk becomes first person to surpass $400 billion net worth: Report
Visual Stories
- NEET UG 2024 result awaited: Top 10 NIRF-ranked medical colleges of India
- 7 New Expected Bullet Train Routes in India
- 10 Upcoming High-Speed Expressways That Will Change Highway Travel In India
- 8 Transformational Indian Railways Projects You Shouldn’t Miss
- Why Sensex, Nifty50 Hit New Highs, M-Cap At $5 Trillion: Top Reasons
UP NEXT
Start a Conversation
Post comment